📈 Today's Market Pulse

🎯 Today's Recap

Friday wrapped up quietly on the surface but carried some real weight underneath. The S&P 500 slipped just 3.47 points to 7,354.02, the Nasdaq shed 60.99 points to 25,297.62, and the Dow dipped 44.51 points to 51,876.11. A calm close, sure, but the stories driving it were anything but calm.

The dollar index fell to 101.33, and 10-year Treasury yields dipped slightly to 4.37%, suggesting bond markets are not entirely convinced we are heading into a rate hike cycle just yet. That said, Minneapolis Fed President Neel Kashkari made headlines by revising his outlook to include one rate increase this year, a statement that added a layer of uncertainty to an otherwise sleepy Friday session.

Bitcoin also nudged lower to $59,698, continuing its week of listless trading. With macro uncertainty creeping back in, risk assets are clearly in wait-and-see mode.

Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next [ad]

📊 Today's Market Movers

▲ Gainers SLS ▲ +17.66% LCID ▲ +15.63% MRNA ▲ +12.59% IBRX ▲ +11.81% CCC ▲ +11.58%

▼ Losers MAAS ▼ -26.82% ON ▼ -23.66% BE ▼ -18.13% RGC ▼ -13.48% WDC ▼ -13.17%

🚀 What Moved Markets

The biggest macro story driving sentiment today is the escalating digital tax standoff between the U.S. and Europe. President Trump threatened a 100% tariff on any country that imposes a digital services tax on American companies. The European Commission fired back, asserting its sovereign right to regulate economic activity. This is not a background noise story. It has real implications for U.S. tech giants operating overseas.

On the stock-specific side, Moderna (MRNA) was the clear winner of the day, surging $7.52 to $67.27 and leading the S&P 500 after unveiling a new cell therapy program. That news pushed shares toward their highest close since late 2024, giving the biopharma sector a rare bright spot. ImmunityBio (IBRX) also caught a bid, climbing $0.92 to $8.71 on broader biotech enthusiasm.

Verizon (VZ) made a significant move in the telecom space, successfully bidding nearly $3.2 billion for mid-band spectrum licenses in an FCC auction. That kind of infrastructure investment signals confidence in long-term 5G expansion, even as capital costs climb.

Backed By Elon Musk, This Could be the Next Hot IPO [ad]

🎭 Investor Mood

Today's mood is best described as cautiously unsettled. Consumer sentiment from the University of Michigan actually rose in June as gasoline prices eased, which is a genuine positive. But Kashkari's rate hike comments are the kind of thing that lingers in investors' minds over a weekend, especially when markets had been pricing in a more dovish path forward.

The whiplash in trending stocks tells a similar story. ON Semiconductor (ON) cratered 28.09 points to 90.65, and Western Digital (WDC) shed a stunning $88.94 to land at $586.45. Meanwhile, Eli Lilly (LLY) somehow gained $80.13, and Sadot Group (SDOT) popped 15.27 points. When the daily movers list looks like that, it means markets are sorting through narratives rather than trading with conviction.

SpaceX's early volatility as a public company adds another layer of speculative noise. The Elon Musk factor is real, and the sharp swings in its first two weeks of trading are a reminder that cult-of-personality stocks carry outsized risk alongside the excitement.

What will Nvidia do next? [ad]

🔍 Tomorrow's Watchlist

1. Monitor EU government responses to Trump's 100% digital tariff threat over the weekend
2. Watch for additional Fed speakers echoing Kashkari's rate hike outlook next week
3. Track Moderna (MRNA) for follow-through buying on its new cell therapy program announcement
4. Keep an eye on the 10-year Treasury yield and whether it retests the 4.5% level
5. SpaceX public market volatility worth watching as a sentiment indicator for speculative risk appetite

💸 The Takeaway

Looking ahead, the digital tax conflict is the thread worth pulling hardest. If Trump follows through on 100% tariff threats against trading partners who tax U.S. tech firms, the fallout would ripple through multinationals in a hurry. Watch how European governments respond over the weekend. Their next move will set the tone for early July trading.

The Kashkari rate hike signal also deserves serious attention. One Fed voice does not make policy, but it shifts the conversation. If more regional Fed presidents echo that view in coming weeks, the bond market will have to reprice quickly. Keep an eye on the 10-year yield and whether it breaks back above 4.5%.

Finally, Moderna's cell therapy announcement is worth monitoring as more details emerge. MRNA has had a brutal stretch since its pandemic highs, and a genuine pipeline catalyst could attract fresh institutional interest. Biotech as a whole may be worth watching as a sector to revisit if this momentum holds into next week.

Jim Rickards: “Trump’s Secret $2 Stock?” [ad]